Titan Pharma Inc (TTNP) 0.6500 $TTNP
Titan Pharmaceuticals Announces Second Quarter 2014 Financial Results
Marketwire - Wed Aug 13, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence and other serious medical disorders, today reported financial results for the second quarter ended June 30, 2014.
Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2014 Financial Results
Marketwire - Thu Aug 07, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Thursday, Aug. 14, 2014 to discuss the company's financial results as of June 30, 2014. The call will be hosted by Sunil Bhonsle, president; Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the second quarter and financial results will be included in a press release to be issued prior to the call.
Titan Pharmaceuticals Announces First Patient Enrollment in Clinical Study of Probuphine for Opioid Dependence
Marketwire - Mon Jul 21, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced enrollment of the first patients in the Phase 3 clinical study to support resubmission of the New Drug Application (NDA) for Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. The study, which is expected to be completed by the middle of 2015, is designed to address key questions posed by the U.S. Food and Drug Administration (FDA) in its complete response letter last year after review of the original NDA. Titan's partner Braeburn Pharmaceuticals is sponsoring the trial and anticipates resubmission of the NDA to the FDA in late 2015.
Highline Research Advisors Initiates on Titan Pharmaceuticals with a Buy Rating
Thomson Reuters ONE - Mon Jul 07, 9:44AM CDT
SAN FRANCISCO - July 7, 2014 -Michael Higgins from Highline Research Advisors, part of Financial Entrepreneur Platform at Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that it has initiated equity research coverage of Titan Pharmaceuticals, Inc. (OTCQB: TTNP) with a Buy rating and a $3.00 price target.
Titan Pharmaceuticals Announces Fourth Quarter and Year End 2013 Financial Results
Marketwire - Mon Mar 31, 6:02AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the fourth quarter and year ended December 31, 2013.
Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Wed Mar 26, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Tuesday, April 1, 2014 to discuss the company's financial results as of December 31, 2013. The call will be hosted by Sunil Bhonsle, president; Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman.
Titan Pharmaceuticals Announces Agreement in Principle on Path Forward for Probuphine Clinical Study
Marketwire - Mon Mar 03, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that the company and its partner, Braeburn Pharmaceuticals, have agreed in principle with the U.S. Food and Drug Administration (FDA) on the design of a clinical study in support of the New Drug Application (NDA) for Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. The proposed clinical study will be a randomized, double blind and double dummy design that will provide information for a non-inferiority comparison of a six-month treatment with a dose of four Probuphine implants to treatment with 8mg or less of an approved daily dosed sublingual formulation of buprenorphine. Details of the study, including size and the data analysis plan, will be established following the FDA's review of a complete study protocol, which Braeburn expects to submit within the next two weeks.
CSE: 2014-0205-Name and Symbol Change-Synergy Acquisition Corp. (QMP)
Marketwire Canada - Wed Feb 12, 10:20AM CST
Synergy Acquisition Corp. has announced a name change to Genius Properties Ltd.
Spectra7 Announces Promotion Of Melissa Chee To Vice President Of Corporate Marketing And Product Management
PR Newswire - Tue Feb 04, 8:00AM CST
(TSX-V:SEV) Spectra7 Microsystems Inc. ("Spectra7" , a high performance analog semiconductor company delivering unprecedented speed, resolution and signal fidelity to consumer and wireless infrastructure products, today announced that Melissa Chee has been promoted to Vice President of Corporate Marketing and Product Management for the Company.
SecurityMetrics PCI Suite Named Finalist in Info Security Products Guide Global Excellence Awards
PR Newswire - Thu Jan 16, 12:18PM CST
Info Security Products Guide, the industry's leading information security research and advisory guide, has named SecurityMetrics PCI Suite a finalist for the 10th Annual 2014 Global Excellence Awards in the PCI Compliance category. These prestigious global awards recognize security and IT vendors with advanced products and solutions that help set the bar higher for others in all areas of security and technology.
Esri's Location Platform Brings the Power of Place to Microsoft Dynamics CRM
PR Newswire - Tue Jan 07, 1:45PM CST
Esri today announced the release of an enhanced Esri Maps for Microsoft Dynamics CRM. The software adds new analytical perspectives for retailers across the omni-channel. From a single store to the entire supply-chain, users can collaborate to author and share analytical intelligence on customers, stores, products, markets, and the competition with a wealth of demographic data for 120 countries.
Titan Pharmaceuticals Receives Official Minutes From FDA Meeting on Probuphine New Drug Application
Marketwire - Mon Dec 23, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced the receipt of the official minutes (the "Minutes" from a Type C meeting with the U.S. Food and Drug Administration (FDA) on November 19, 2013 to discuss the Complete Response Letter (CRL) to its New Drug Application (NDA) for Probuphine(R), an investigational subdermal implant for the maintenance treatment of opioid dependence in adult patients. Per the Minutes, the FDA emphasized its commitment to working with Titan and its partner, Braeburn Pharmaceuticals, to pursue a reasonable path to approval, and all parties agreed that seeking an indication in individuals stabilized on 8 mg/day or less of sublingual buprenorphine (SL BPN) may be a suitable approval pathway for Probuphine. Titan and Braeburn proposed the revised indication following a review of the FDA's comments on the briefing material and to address one of the primary concerns in the CRL regarding dose adequacy among the original study population (newly inducted patients maintained at 12-16 mg SL BPN/day). The FDA maintained the need for clinical data in this patient population as a requirement for approval, stipulating that the study "need not be large," "be adequate and well-controlled," and "must support labeling for the duration of treatment (6 months)." Titan and Braeburn are working with experts in the field to develop a clinical study design for submission to the FDA within the next few weeks.
Cambridge University Press picks DayNine Consulting management tool
M2 - Wed Dec 18, 8:25AM CST
Workday (NYSE: WDAY) services partner DayNine Consulting said it was selected by Cambridge University Press to deploy its Workday Human Capital Management solution.
Titan Pharmaceuticals Announces Submission of FDA Meeting Request Regarding Probuphine
Marketwire - Wed Sep 04, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced the submission of a Type B meeting request to the U.S. Food and Drug Administration (FDA) to discuss Probuphine(R), the company's investigational subdermal implant designed to deliver continuous, blood levels of buprenorphine for six months following a single treatment.
Titan Pharmaceuticals Announces Publication of Phase 3 Probuphine Data in Addiction
Marketwire - Tue Aug 13, 4:03PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that data from its previously completed and announced Phase 3 placebo- and active drug-controlled confirmatory clinical study of Probuphine(R), evaluating the safety and efficacy of its subdermal implant for the maintenance treatment of opioid dependence in adult patients, were published online in the journal Addiction. The paper is expected to appear in a future print issue of the journal.
Titan Pharmaceuticals Announces Amendment to Partnership With Braeburn Pharmaceuticals
Marketwire - Wed May 29, 3:05PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has entered into an amendment to its license agreement with Braeburn Pharmaceuticals Sprl for the exclusive commercialization rights in the U.S. and Canada to the investigational product Probuphine(R), a novel, subdermal implant and the first long-acting product designed to deliver six months of the drug buprenorphine following a single treatment. The amendment primarily modifies certain of the agreement's termination provisions by providing Braeburn the right to terminate the license in the event significant additional clinical work or a material change to the product label will be required by the U.S. Food and Drug Administration (FDA) as a condition to approval of the New Drug Application (NDA) or if the NDA is not approved by June 30, 2014.
Titan Pharmaceuticals Inc swings to net income of USD6.0m for Q1 2013
M2 - Thu May 16, 8:30AM CDT
Biopharmaceutical company Titan Pharmaceuticals Inc (OTCBB:TTNP) stated on Wednesday its net income of USD6.0m (USD0.08 per share) for the first quarter ended 31 March 2013.
Titan Pharmaceuticals Announces First Quarter 2013 Financial Results
Marketwire - Wed May 15, 7:30PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the first quarter ended March 31, 2013.
Titan Pharmaceuticals Announces Second Quarter 2014 Financial Results
Marketwire - Wed Aug 13, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence and other serious medical disorders, today reported financial results for the second quarter ended June 30, 2014.
Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2014 Financial Results
Marketwire - Thu Aug 07, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Thursday, Aug. 14, 2014 to discuss the company's financial results as of June 30, 2014. The call will be hosted by Sunil Bhonsle, president; Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the second quarter and financial results will be included in a press release to be issued prior to the call.
Titan Pharmaceuticals Announces First Patient Enrollment in Clinical Study of Probuphine for Opioid Dependence
Marketwire - Mon Jul 21, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced enrollment of the first patients in the Phase 3 clinical study to support resubmission of the New Drug Application (NDA) for Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. The study, which is expected to be completed by the middle of 2015, is designed to address key questions posed by the U.S. Food and Drug Administration (FDA) in its complete response letter last year after review of the original NDA. Titan's partner Braeburn Pharmaceuticals is sponsoring the trial and anticipates resubmission of the NDA to the FDA in late 2015.
Highline Research Advisors Initiates on Titan Pharmaceuticals with a Buy Rating
Thomson Reuters ONE - Mon Jul 07, 9:44AM CDT
SAN FRANCISCO - July 7, 2014 -Michael Higgins from Highline Research Advisors, part of Financial Entrepreneur Platform at Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that it has initiated equity research coverage of Titan Pharmaceuticals, Inc. (OTCQB: TTNP) with a Buy rating and a $3.00 price target. Titan Pharmaceuticals Announces Fourth Quarter and Year End 2013 Financial Results
Marketwire - Mon Mar 31, 6:02AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the fourth quarter and year ended December 31, 2013.
Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Wed Mar 26, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Tuesday, April 1, 2014 to discuss the company's financial results as of December 31, 2013. The call will be hosted by Sunil Bhonsle, president; Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman.
Titan Pharmaceuticals Announces Agreement in Principle on Path Forward for Probuphine Clinical Study
Marketwire - Mon Mar 03, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that the company and its partner, Braeburn Pharmaceuticals, have agreed in principle with the U.S. Food and Drug Administration (FDA) on the design of a clinical study in support of the New Drug Application (NDA) for Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. The proposed clinical study will be a randomized, double blind and double dummy design that will provide information for a non-inferiority comparison of a six-month treatment with a dose of four Probuphine implants to treatment with 8mg or less of an approved daily dosed sublingual formulation of buprenorphine. Details of the study, including size and the data analysis plan, will be established following the FDA's review of a complete study protocol, which Braeburn expects to submit within the next two weeks.
CSE: 2014-0205-Name and Symbol Change-Synergy Acquisition Corp. (QMP)
Marketwire Canada - Wed Feb 12, 10:20AM CST
Synergy Acquisition Corp. has announced a name change to Genius Properties Ltd.
Spectra7 Announces Promotion Of Melissa Chee To Vice President Of Corporate Marketing And Product Management
PR Newswire - Tue Feb 04, 8:00AM CST
(TSX-V:SEV) Spectra7 Microsystems Inc. ("Spectra7"
, a high performance analog semiconductor company delivering unprecedented speed, resolution and signal fidelity to consumer and wireless infrastructure products, today announced that Melissa Chee has been promoted to Vice President of Corporate Marketing and Product Management for the Company. SecurityMetrics PCI Suite Named Finalist in Info Security Products Guide Global Excellence Awards
PR Newswire - Thu Jan 16, 12:18PM CST
Info Security Products Guide, the industry's leading information security research and advisory guide, has named SecurityMetrics PCI Suite a finalist for the 10th Annual 2014 Global Excellence Awards in the PCI Compliance category. These prestigious global awards recognize security and IT vendors with advanced products and solutions that help set the bar higher for others in all areas of security and technology.
Esri's Location Platform Brings the Power of Place to Microsoft Dynamics CRM
PR Newswire - Tue Jan 07, 1:45PM CST
Esri today announced the release of an enhanced Esri Maps for Microsoft Dynamics CRM. The software adds new analytical perspectives for retailers across the omni-channel. From a single store to the entire supply-chain, users can collaborate to author and share analytical intelligence on customers, stores, products, markets, and the competition with a wealth of demographic data for 120 countries.
Titan Pharmaceuticals Receives Official Minutes From FDA Meeting on Probuphine New Drug Application
Marketwire - Mon Dec 23, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced the receipt of the official minutes (the "Minutes"
from a Type C meeting with the U.S. Food and Drug Administration (FDA) on November 19, 2013 to discuss the Complete Response Letter (CRL) to its New Drug Application (NDA) for Probuphine(R), an investigational subdermal implant for the maintenance treatment of opioid dependence in adult patients. Per the Minutes, the FDA emphasized its commitment to working with Titan and its partner, Braeburn Pharmaceuticals, to pursue a reasonable path to approval, and all parties agreed that seeking an indication in individuals stabilized on 8 mg/day or less of sublingual buprenorphine (SL BPN) may be a suitable approval pathway for Probuphine. Titan and Braeburn proposed the revised indication following a review of the FDA's comments on the briefing material and to address one of the primary concerns in the CRL regarding dose adequacy among the original study population (newly inducted patients maintained at 12-16 mg SL BPN/day). The FDA maintained the need for clinical data in this patient population as a requirement for approval, stipulating that the study "need not be large," "be adequate and well-controlled," and "must support labeling for the duration of treatment (6 months)." Titan and Braeburn are working with experts in the field to develop a clinical study design for submission to the FDA within the next few weeks. Cambridge University Press picks DayNine Consulting management tool
M2 - Wed Dec 18, 8:25AM CST
Workday (NYSE: WDAY) services partner DayNine Consulting said it was selected by Cambridge University Press to deploy its Workday Human Capital Management solution.
Titan Pharmaceuticals Announces Submission of FDA Meeting Request Regarding Probuphine
Marketwire - Wed Sep 04, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced the submission of a Type B meeting request to the U.S. Food and Drug Administration (FDA) to discuss Probuphine(R), the company's investigational subdermal implant designed to deliver continuous, blood levels of buprenorphine for six months following a single treatment.
Titan Pharmaceuticals Announces Publication of Phase 3 Probuphine Data in Addiction
Marketwire - Tue Aug 13, 4:03PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that data from its previously completed and announced Phase 3 placebo- and active drug-controlled confirmatory clinical study of Probuphine(R), evaluating the safety and efficacy of its subdermal implant for the maintenance treatment of opioid dependence in adult patients, were published online in the journal Addiction. The paper is expected to appear in a future print issue of the journal.
Titan Pharmaceuticals Announces Amendment to Partnership With Braeburn Pharmaceuticals
Marketwire - Wed May 29, 3:05PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has entered into an amendment to its license agreement with Braeburn Pharmaceuticals Sprl for the exclusive commercialization rights in the U.S. and Canada to the investigational product Probuphine(R), a novel, subdermal implant and the first long-acting product designed to deliver six months of the drug buprenorphine following a single treatment. The amendment primarily modifies certain of the agreement's termination provisions by providing Braeburn the right to terminate the license in the event significant additional clinical work or a material change to the product label will be required by the U.S. Food and Drug Administration (FDA) as a condition to approval of the New Drug Application (NDA) or if the NDA is not approved by June 30, 2014.
Titan Pharmaceuticals Inc swings to net income of USD6.0m for Q1 2013
M2 - Thu May 16, 8:30AM CDT
Biopharmaceutical company Titan Pharmaceuticals Inc (OTCBB:TTNP) stated on Wednesday its net income of USD6.0m (USD0.08 per share) for the first quarter ended 31 March 2013.
Titan Pharmaceuticals Announces First Quarter 2013 Financial Results
Marketwire - Wed May 15, 7:30PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the first quarter ended March 31, 2013.
